PROCEPT BioRobotics (PRCT)
(Delayed Data from NSDQ)
$51.83 USD
-0.45 (-0.86%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $51.80 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PRCT 51.83 -0.45(-0.86%)
Will PRCT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PRCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRCT
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
Masimo (MASI) Soars 3.3%: Is Further Upside Left in the Stock?
PRCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
Earnings Preview: Integra LifeSciences (IART) Q4 Earnings Expected to Decline
Other News for PRCT
Analysts Are Bullish on These Healthcare Stocks: Accolade (ACCD), PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
Procept BioRobotics announces 12 scientific research presentations
PROCEPT BioRobotics Announces Board Member Transition
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas